▌技術簡介(現況)

1. 抗體藥物複合體(Antibody-drug conjugates)能夠同時保有抗體藥物的高選擇性及小分子抗癌藥物的高活性，能夠在不產生嚴重副作用的條件下，對癌症進行有效治療，增加患者的壽命及生活品質。

2. 候選藥物具有新標的、專利性、高活性等特點，並屬於first-in-class之新藥，深具國際競爭力與開發潛力。

 

▌技術規格

高選擇性ADC鍵接技術

 

▌技術特色

1. In vitro & in vivo 抗體藥物複合體藥物篩選平台

2. 具專利性之單株抗體選擇性鍵結技術 (已申請台灣及國際專利案-PCT, US)

3. 抗體藥物複合體構築、分析及鑑定技術平台

4. First-in-class anti-Globo H之抗體藥物複合體候選藥物

 

▌應用範圍

癌症治療

 

▌接受技術者具備基礎建議（設備）

 

具新藥開發能力

 

▌接受技術者具備基礎建議（專業）

具備新藥臨床開發經驗或承接能力者

 

▌技術分類

抗體藥物開發

 

▌專利狀態

已申請美國、PCT、中華民國專利

聯絡人：廖宜亭

TEL：02-7700-3800 # 5297

E-mail：jessieliao@dcb.org.tw

 

最後更新日期：2019.03.27

 

Technology/ Title

Development of anti-Globo H ADC against Cancer

Technology Type

□Biotechnology

□Device/Diagnostics

■Pharmaceutical

□Others:_____________-

Contact Person

Name: Joseph Liu

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5237

Mobile:

Email: joseph.liu@dcb.org.tw

 

 

Technology Description

 

Summary of Invention:

1.      Antibody-drug conjugates (ADC) is one of the most important approach in recent cancer drug development. ADCs contain an antibody and high potent cytotoxic drugs and these two parts are connected with a specific linker. ADCs can target to the tumor cells through the antibody part by recognizing and binding to correspond tumor antigen. After internalization, the ADCs was cleaved or digested in lysosome or endosome and cytotoxic drugs were released to kill the cancer cells.

2.      The ADC candidate compound show great tumor inhibition via a novel target, and belongs to first-in-class drug development.

 

Advantages when compared to the existing technologies:

  1. In vitro & in vivo platforms for ADC screening.
  2. Novel site-specific conjugation method for ADC products.
  3. Characterization and analytical platforms for ADC.
  4. Pre-clinical development ADC candidate with novel targeting antibody.

Intellectual Property

US, PCT, Taiwan patent were filed

Key Publications

 

 

Business Opportunity

Next generation antibody related in cancer therapy